Cell and gene therapy companies are navigating a commercialization environment unlike any other in biopharma. Products are manufactured individually or in small batches, often at contract development and manufacturing organizations (CDMOs). Hospital treatment centers require specialized training and certification. Regulatory submissions involve novel frameworks. And the billing and administrative workflows that connect these elements are unusually complex. In 2026, cell and gene therapy developers are deploying virtual assistants to manage the administrative infrastructure surrounding their manufacturing, clinical, and regulatory operations.
CDMO Manufacturing Contract Billing
Manufacturing relationships for advanced therapies involve detailed contract structures: batch production milestones, technology transfer deliverables, process validation events, and regulatory filing support fees. Billing against these contracts requires tracking completion of specific manufacturing activities, assembling supporting documentation, and coordinating approval workflows between operations and finance.
IQVIA's 2025 advanced therapy manufacturing report found that CDMO contract billing disputes are disproportionately common in the cell and gene therapy sector relative to conventional biologics manufacturing, driven by the complexity of milestone definitions and the novelty of production processes. Virtual assistants trained in contract-based billing are supporting the tracking and documentation layer: monitoring milestone status in project management systems, assembling completion evidence packages, processing invoices against purchase orders, and tracking payment timelines.
For companies managing relationships with multiple CDMOs simultaneously — a common situation for developers building redundant manufacturing capacity — VA support for billing coordination reduces the risk of invoice errors and delayed payments that can strain manufacturing partner relationships.
Hospital and Treatment Center Administration
Commercial and late-stage cell and gene therapy programs require an extensive network of certified treatment centers — hospitals and academic medical centers whose staff must be trained, credentialed, and operationally prepared to administer the therapy. Managing the administrative side of this hospital network is a significant ongoing commitment.
Site onboarding documentation, training scheduling, credentialing record maintenance, treatment scheduling coordination, and patient logistics support all generate administrative volume that commercial teams must manage. Virtual assistants are handling defined segments of this coordination: scheduling site training sessions, tracking site certification status, distributing protocol update communications, and maintaining treatment center contact databases.
Deloitte's 2025 Life Sciences Outlook found that cell and gene therapy commercial operations teams routinely identify hospital network administration as a top source of operational strain, with administrative coordination consuming more than 40 percent of field medical and commercial coordinator time in launch-stage companies.
Regulatory Filing Coordination
Advanced therapy regulatory submissions involve multiple agency interactions — BLA filings with FDA, MAA submissions with EMA, manufacturing facility inspections, post-approval manufacturing change submissions — each requiring careful document management. Companies operating across multiple geographic markets simultaneously face particularly complex regulatory administrative demands.
Virtual assistants are supporting the document coordination layer of regulatory submissions: organizing document collection, tracking submission component deadlines, formatting documents to agency templates, and maintaining regulatory correspondence logs. This positions regulatory affairs professionals to focus on substantive submission content and agency interaction strategy.
The Advanced Therapy Medicinal Products (ATMP) sector saw a 35 percent increase in active regulatory submissions between 2022 and 2025, according to Evaluate Pharma's 2025 advanced therapy report, significantly expanding the administrative workload at companies active in the space.
Patient Access and Reimbursement Administration
Patient access programs for advanced therapies — which often carry price tags of $500,000 to several million dollars per treatment — involve intensive reimbursement coordination. Prior authorization support, outcome-based contract documentation, and outcomes tracking for payer agreements generate ongoing administrative requirements.
Virtual assistants trained in specialty pharmaceutical access workflows are supporting the administrative layer of patient access programs: tracking prior authorization status, coordinating outcomes data collection for payer contracts, and managing patient assistance program documentation. This allows market access specialists to focus on payer strategy rather than transactional documentation.
McKinsey's 2024 advanced therapy commercialization analysis identified patient access administration as one of the highest-impact areas for operational support investment in the cell and gene therapy sector.
Cell and gene therapy companies looking to improve CDMO billing efficiency, hospital network administration, and regulatory coordination can explore virtual assistant models at Stealth Agents.
Sources
- IQVIA, Advanced Therapy Manufacturing Report, 2025
- Deloitte, 2025 Life Sciences Outlook, 2025
- Evaluate Pharma, Advanced Therapy Sector Report, 2025